UPDATE: GlobeImmune (GBIM) Reports Q1 Loss Per Share of 15c, Continues to Evaluate Strategic Alternatives

(Update correct comparable figure to year-over-year results, not analyst estimates)

GlobeImmune (NASDAQ: GBIM) reported Q1 EPS of ($0.15), $0.12 better than last year ($0.27).

At March 31, 2016, GlobeImmune had cash and equivalents of $8.7 million. The Company believes it has sufficient cash to operate the company as a going concern through the middle of 2017 as it continues to evaluate strategic alternatives. If a strategic alternative is not found in the near future, we could decide to wind down the operations of the Company which will consume cash faster than currently planned as a going concern.

For earnings history and earnings-related data on GlobeImmune (GBIM) click here.

You May Also Be Interested In

• Ocean Power Technologies revises fiscal 2026 results after audit
• Unifi, Inc. (UFI) Misses Q4 EPS by 11c
• John B. Sanfilippo & Son (JBSS) Misses Q4 EPS by 59c